403 Shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC) Bought by Sachetta LLC

Sachetta LLC bought a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 403 shares of the company’s stock, valued at approximately $31,000.

Several other institutional investors also recently bought and sold shares of GEHC. Janney Capital Management LLC grew its position in shares of GE HealthCare Technologies by 4.7% in the fourth quarter. Janney Capital Management LLC now owns 3,289 shares of the company’s stock valued at $254,000 after purchasing an additional 149 shares during the last quarter. American National Bank grew its position in shares of GE HealthCare Technologies by 25.2% in the fourth quarter. American National Bank now owns 750 shares of the company’s stock valued at $58,000 after purchasing an additional 151 shares during the last quarter. Chilton Capital Management LLC grew its position in shares of GE HealthCare Technologies by 15.4% in the fourth quarter. Chilton Capital Management LLC now owns 1,227 shares of the company’s stock valued at $95,000 after purchasing an additional 164 shares during the last quarter. Procyon Advisors LLC grew its position in GE HealthCare Technologies by 5.2% during the fourth quarter. Procyon Advisors LLC now owns 3,555 shares of the company’s stock worth $275,000 after buying an additional 175 shares in the last quarter. Finally, 9258 Wealth Management LLC grew its position in GE HealthCare Technologies by 5.7% during the fourth quarter. 9258 Wealth Management LLC now owns 3,273 shares of the company’s stock worth $253,000 after buying an additional 176 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Stock Performance

NASDAQ:GEHC opened at $80.62 on Thursday. GE HealthCare Technologies Inc. has a 1 year low of $62.35 and a 1 year high of $94.50. The firm has a 50 day moving average of $85.49 and a 200-day moving average of $80.42. The company has a current ratio of 1.06, a quick ratio of 0.83 and a debt-to-equity ratio of 1.11. The stock has a market capitalization of $36.80 billion, a P/E ratio of 23.57, a price-to-earnings-growth ratio of 2.95 and a beta of 1.26.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.90 earnings per share for the quarter, hitting the consensus estimate of $0.90. The firm had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.80 billion. GE HealthCare Technologies had a net margin of 8.05% and a return on equity of 25.32%. GE HealthCare Technologies’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.85 EPS. As a group, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th were given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.15%. The ex-dividend date was Thursday, April 18th. GE HealthCare Technologies’s payout ratio is 3.51%.

Analysts Set New Price Targets

GEHC has been the topic of a number of recent research reports. Citigroup lifted their target price on GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Bank of America decreased their target price on GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. Morgan Stanley lifted their target price on GE HealthCare Technologies from $74.00 to $86.00 and gave the stock an “equal weight” rating in a research report on Monday, February 12th. UBS Group raised GE HealthCare Technologies from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $66.00 to $88.00 in a report on Monday, February 12th. Finally, Mizuho decreased their price objective on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $94.80.

Insider Activity

In related news, insider Frank R. Jimenez bought 1,315 shares of GE HealthCare Technologies stock in a transaction that occurred on Wednesday, May 1st. The stock was purchased at an average cost of $76.52 per share, with a total value of $100,623.80. Following the purchase, the insider now owns 75,796 shares in the company, valued at $5,799,909.92. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other GE HealthCare Technologies news, CEO Jan Makela sold 66,955 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $81.54, for a total value of $5,459,510.70. Following the transaction, the chief executive officer now directly owns 63,348 shares of the company’s stock, valued at approximately $5,165,395.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Frank R. Jimenez bought 1,315 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were acquired at an average price of $76.52 per share, for a total transaction of $100,623.80. Following the transaction, the insider now owns 75,796 shares in the company, valued at $5,799,909.92. The disclosure for this purchase can be found here. 0.27% of the stock is owned by company insiders.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.